Stanley Laman Group Ltd. Acquires Shares of 11,074 Organon & Co. (NYSE:OGN)

Stanley Laman Group Ltd. acquired a new stake in Organon & Co. (NYSE:OGN) in the 4th quarter, Holdings Channel reports. The fund acquired 11,074 shares of the company’s stock, valued at approximately $165,000.

Several other large investors also recently bought and sold shares of OGN. Sippican Capital Advisors raised its holdings in Organon & Co. by 4.3% during the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after purchasing an additional 627 shares in the last quarter. Commerce Bank raised its holdings in Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after purchasing an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares in the last quarter. Graypoint LLC raised its holdings in Organon & Co. by 6.2% during the third quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after purchasing an additional 853 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its holdings in Organon & Co. by 12.9% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 10,910 shares of the company’s stock worth $163,000 after purchasing an additional 1,248 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Trading Up 11.0 %

Shares of OGN opened at $16.31 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm’s 50-day moving average is $15.34 and its two-hundred day moving average is $17.53. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The firm has a market capitalization of $4.20 billion, a P/E ratio of 3.24, a PEG ratio of 0.83 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. On average, research analysts predict that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.